Clay Siegall Aim to Revolutionize Cancer Treatment

Clay Siegall, Ph.D. is the co-founder of Seattle Genetics. He started the company in 1998, and he is its president, CEO, and board chairman. Being a professional scientist with emphasis on cancer therapies, he founded Seattle Genetics on the grounds of rigorous research, scientific innovation, drug development practices, and a passion for aiding cancer patients. Under his leadership, Siegall has guided the firm to its current pioneering status in the development of ADCs and in obtaining the 2011 FDA approval of ADCETRIS. Collaboration with the Takeda Pharmaceutical has made ADCETRIS be a global brand that has been accepted in over 60 countries.

 

Siegall’s motivation and business strategy

 

Seattle Genetics is primarily focused on helping patients. Siegel claims that seeing the misery his father went through while suffering from cancer is what made him aware of how limited the tools were to oncologists, and now he wanted to improve the tools. After earning his Genetics doctorate from George Washington University, he spent some years working at Pharmaceutical Research Institute. It was during this time that he learned how to manage a company.

 

Siegall claims that when people are in their 20’s, they tend to think that they know everything. Upon reaching 30’s, they kind of recognize that they don’t. Siegall, now in his 40’s, appreciates that he does not know much, and he always tries to learn as more as he can grasp. He believes interacting with smart people who are experts in various fields is the best way that a person can learn much.

 

Siegel explains that collaborating with other innovators and industry leaders in cancer drug development is one of the important components of their business strategy. Siegall insists that their ADC collaborations have helped in extending their technological reach, hence giving them room to put resources into new approaches and ideas that will help patients.

 

Dr. Siegall has steered the capital-raising activities of Seattle Genetics into securing over $675 million through private and public financings. Siegall serves on Alder Biopharmaceuticals’ Board of Directors. He holds over a dozen patents and has authored over 70 publications.

 

Leave a Reply